Sell under management, week 14: ADX fading, CMF buying
Phio Pharmaceuticals stock sheds 1.4% as money flow stays on the buy side
Sell under management, week 14: ADX fading, CMF buying
Our view last week
Phio Pharmaceuticals' money flow stays positive for a second straight week, but sellers take back the edge on volume this time: 70% of trading swung to the sell side, versus 88% on the buy side seven days ago. The ADX keeps sliding: the decline keeps losing conviction. The double bottom in the 0.96 area holds for a fourth week, with the short up 12.61%.
This week's summary
Money flow on Phio Pharmaceuticals stock stays firmly on the buy side for a third straight week, yet the ADX keeps sliding: the decline keeps losing conviction. The week closed down 1.4% despite 62% of trading on the buy side, a divergence that reads more like hesitation than strength. Price remains boxed between support in the 0.95 area and resistance in the 1.03 area, with the short over 13% in profit. Worth watching closely: earnings land this week.
IQS Phase
62
ordinary
Signal Strength
17
decline starting to make lower lows
Sizing
MINIMUM
Ranking
#58 / 138
US stocks
Trade P&L %
+13.87%
from signal to date, no stop loss
Rank position
ranks 58th among the 138 sell signals for US stocks in our ranking, with a signal strength of 17 out of 100.
Sector context
SectorHealth Care
Benchmark ETFXLV
Sector regimein positive regime
Performanceweekly -0.01% · monthly +1.89%
PHIO belongs to the health care sector (reference ETF XLV). The sector is classified in positive regime according to our weekly reading.
restricted Platinum content